Oblique Therapeutics recognized as one of the 15 Most Promising Biotech Startups in Europe 2019

GOTHENBURG, Sweden, July 17, 2019 : Oblique Therapeutics, a Swedish biotech focusing on generating novel therapeutic antibodies towards severe diseases such as cancer and pain, has been honored as one of the most promising biotech startup in Europe 2019 by StartUp City magazine. An interview with the CEO, Owe Orwar, is featured on the cover story of the BioTech special issue published this month.

 

StartUp City Magazine: “Oblique Therapeutics is uncovering medical breakthroughs in antibody therapeutics using its proporietary technology platform AbiprotTM”. The AbiprotTM technology enables the development of antibodies against difficult-to-drug targets such as ion channels and certain G-protein-coupled receptors (GPCRs) that can translate into new effective treatment options for large groups of patients in need of new medicines.

 

“It is an honor to receive this recognition, and we are devoted to continue on building and advancing our pipeline with new antibody therapeutics that matters to patients,” says Owe Orwar, CEO